Journal
NEUROLOGICAL SCIENCES
Volume 42, Issue SUPPL 1, Pages 29-36Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-021-05116-2
Keywords
Fingolimod; Interferon beta-1a; Pediatric onset multiple sclerosis; Long-term treatment
Categories
Funding
- Novartis Farma, Italy
Ask authors/readers for more resources
The data suggest that early initiation of disease-modifying therapy is essential for patients with pediatric-onset multiple sclerosis (POMS) to slow progression. Two cases presented in the study demonstrated sustained clinical benefit from treatment with fingolimod for more than 2 years, indicating its safety and effectiveness as first- or second-line therapy in children with POMS.
Data suggest that patients with pediatric-onset multiple sclerosis (POMS) should initiate treatment with a disease-modifying therapy early to slow progression. The PARADIGMS trial demonstrated that oral fingolimod reduced the annual rate of relapse by 82% compared with intramuscular interferon beta-1a in children with POMS. The PARADIGMS study had a follow-up of 2 years, but no data are available about the safety and efficacy of fingolimod for longer periods in children with POMS. Here we present two cases of children with POMS who achieved sustained clinical benefit from treatment with fingolimod for more than 2 years. The first patient, an 11-year-old male, who participate in the PARADIGMS study, was treatment naive at the time of fingolimod initiation. His clinical condition remained stable over 5 years of treatment, with no relapses and no radiological lesion progression. The second patient was a female who initiated fingolimod at the age of 12 years, 2 years after her POMS diagnosis and after an 8-month trial of interferon beta-1a. The patient had experienced two relapses during interferon beta-1a but had no relapses in more than 2 years of treatment with fingolimod, and her MRI scans showed no new or active lesions. These data show that prolonged treatment with fingolimod can be safe and effective during long-term treatment as first- or second-line therapy in children with POMS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available